Breezula/Winlevi
    8/17/2020

    New to Clascoterone? There is a guide in the encyclopedia. Read the guide →
    At a glance
    In this question or advice post, the primary subjects mentioned are
    💧 Breezula (topical) 7.5%
    💧 Winlevi (topical) 1%
    the tone is 😐 neutral.

    Other terms

    Breezula/Winlevi's potential use for hair loss is discussed, with concerns about its effectiveness compared to Breezula's higher concentration. Users express interest in a topical treatment with minimal side effects, noting that Breezula's efficacy may decline after six months.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community Breezula is the final brick in the wall

       36 upvotes 2 months ago
      Breezula is discussed as a potential topical anti-androgen treatment for hair loss, with mixed opinions on its effectiveness and side effects compared to other treatments like finasteride, minoxidil, and RU58841. Some users express skepticism about its long-term efficacy and potential side effects, while others are hopeful for its approval and use in combination with existing treatments.

      community Pyrludimide (KX-826) or Breezula (clascoterone)

       9 upvotes 5 months ago
      The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

      community Why Breezula Won’t Work for Everyone.

       30 upvotes 8 months ago
      Breezula, a new topical hair loss treatment, is expected to be expensive, with an estimated cost of €300 per month, making it less accessible compared to cheaper alternatives like finasteride. Some users discuss the potential for cheaper generics from countries like China and India, while others debate the effectiveness and pricing strategy of Breezula compared to other treatments like minoxidil and RU58841.

      community Breezula Phase III 12-Month Data Released by Cosmo Pharma

       42 upvotes 5 months ago
      Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

      community What do we currently know about clascoterone?

       7 upvotes 8 months ago
      Clascoterone is seen as a promising topical treatment for hair loss, similar to finasteride but without side effects, though concerns exist about its long-term effectiveness. Other treatments discussed include topical minoxidil, ketoconazole, microneedling, and oral options like dutasteride and minoxidil.

    Related Research

    6 / 6 results
      Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris

      research Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris

      7 citations , December 2019 in “American Journal of Clinical Dermatology”
      This review discusses the potential efficacy of topical antiandrogen therapies for treating androgenetic alopecia and acne vulgaris, finding promising results but highlighting the need for more comprehensive studies.
      Recent Advances in Drug Development for Hair Loss

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
      New Therapeutics in the Management of Androgenetic Alopecia

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
      Industry Update: The Latest Developments in the Field of Therapeutic Delivery, July 2018

      research Industry update: the latest developments in the field of therapeutic delivery, July 2018

      1 citations , November 2018 in “Therapeutic Delivery”
      This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.

      research Clascoterone: First Approval

      27 citations , October 2020 in “Drugs”
      This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.